-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Lopinavir-d8
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1224729-35-4.gif)
| Category | HIV Protease |
| CAS | 1224729-35-4 |
| Description | Lopinavir-d8 (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM. |
Product Information
| Synonyms | Lopinavir-d8|1322625-54-6|2,3,4,4,4-pentadeuterio-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-2-(2-oxo-1,3-diazinan-1-yl)-3-(trideuteriomethyl)butanamide |
| Molecular Weight | 636.85 |
| Molecular Formula | C37H48N4O5 |
| Canonical SMILES | CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O |
| Boiling Point | 924.2±65.0 °C at 760 mmHg |
| Flash Point | 512.7±34.3 °C |
| Purity | ≥98% (HPLC) |
| Density | 1.2±0.1 g/cm3 |
| Solubility | Chloroform: Slightly Soluble,Methanol: Slightly Soluble |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 940 |
| Exact Mass | 636.41268461 |
| Index Of Refraction | 1.577 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | HIV; HIV Protease; SARS-CoV |
| Vapor Pressure | 0.0±0.3 mmHg at 25°C |
| XLogP3-AA | 5.9 |
